13F Holdings
中文EN

NXTC NextCure, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—

Leverage & solvency

Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$44.92M$41.49M$47.93M$54.20M$50.19M
SG&A expense$12.69M$15.72M$19.71M$21.71M$20.57M
Operating income-$57.62M-$59.75M-$67.64M-$75.91M-$70.77M
Income tax$0————
Net income-$55.84M-$55.65M-$62.72M-$74.73M-$69.39M
EBITDA-$55.42M-$56.85M-$63.94M-$71.81M-$66.47M
EPS (basic)-19.65-23.88-2.25-2.69-2.51
EPS (diluted)-19.65-23.88-2.25-2.69-2.51
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)2.84M2.33M27.84M27.74M27.62M
Balance sheet
Cash & equivalents$25.98M$27.73M$13.08M$26.63M$12.34M
Current assets$43.75M$71.81M$112.72M$163.98M$227.82M
PP&E, net$3.27M$5.46M$9.03M$11.90M$13.99M
Total assets$50.18M$80.86M$128.04M$184.16M$242.39M
Current liabilities$10.57M$9.57M$6.88M$9.13M$6.61M
Long-term debt———$0$0
Total debt———$0$0
Total liabilities$15.24M$15.39M$13.62M$16.63M$9.00M
Shareholders' equity$34.94M$65.47M$114.42M$167.53M$233.39M
Net debt———-$26.63M-$12.34M
Shares outstanding3.51M2.33M27.90M27.77M27.68M
Cash flow statement
Operating cash flow-$49.61M-$40.80M-$52.97M-$53.89M-$57.28M
Capital expenditure—$474,000$820,000$2.12M$2.36M
Free cash flow—-$41.28M-$53.79M-$56.00M-$59.64M
Investing cash flow$25.56M$55.31M$39.27M$67.98M$36.60M
Financing cash flow$22.31M$144,000$154,000$200,000-$3.27M
Depreciation & amortization$2.20M$2.90M$3.70M$4.10M$4.30M
Stock-based compensation$2.99M$6.33M$8.19M$9.51M$10.29M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.